Dr. Burns on Key Advances Made in RET+ NSCLC
Timothy F. Burns, MD, PhD, discusses key developments in the frontline treatment of patients with RET-positive non–small cell lung cancer.
Dr. Burns on the Promise of Combination Regimens in EGFR Exon 20 Insertion+ and KRAS+ NSCLC
Timothy F. Burns, MD, PhD, discusses the promise of combination regimens for patients with EGFR exon 20 insertion– and KRAS G12C–mutated non–small cell lung cancer.
Dr. Burns on Identifying Genetic Alterations in Lung Cancer
Timothy F. Burns, MD, PhD, discusses methods of identifying genetic alterations in lung cancer.
Currently Available Treatment Options for Patients With R/R DLBCL
Overview of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)
Both Gastric and Breast HER2 Scoring Algorithms Applicable in mCRC Testing
Encorafenib Plus Cetuximab and Chemotherapy Demonstrates Safety, Efficacy in BRAF V600E–Mutant mCRC
2 Clarke Drive Cranbury, NJ 08512